Allogene Therapeutics (ALLO) Other Non-Current Assets (2018 - 2026)
Allogene Therapeutics (ALLO) posted Other Non-Current Assets of $3.5 million for Q1 2026, down 2.32% sequentially from $3.6 million in Q4 2025, and down 65.69% YoY from $10.3 million in Q1 2025.
Allogene Therapeutics (ALLO) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Other Non-Current Assets for 9 years, with the latest figure at $3.5 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 65.69% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (down 65.69% YoY) and the FY2025 annual result came in at $3.6 million, down 64.88% from the prior year.
- Other Non-Current Assets retreated to $3.5 million in Q1 2026 per ALLO's latest filing, from $3.6 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $10.3 million in Q1 2022 and troughed at $3.5 million in Q3 2025.
- A 5-year average of $8.3 million and a median of $9.6 million in 2023 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 99.5% in 2025, down 65.87% in 2025.
- Over 5 years, Other Non-Current Assets stood at $10.3 million in 2022, then changed by 0.0% to $10.3 million in 2023, then changed by 0.0% to $10.3 million in 2024, then tumbled by 64.88% to $3.6 million in 2025, then slipped by 2.32% to $3.5 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $3.5 million, $3.6 million, and $3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 10.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.29 Mn |
| Mar 31, 2026 | 3.53 Mn |
| Dec 31, 2025 | 3.62 Mn |
| Sep 30, 2025 | 3.51 Mn |
| Jun 30, 2025 | 10.29 Mn |
| Mar 31, 2025 | 10.29 Mn |
| Dec 31, 2024 | 10.29 Mn |
| Sep 30, 2024 | 10.29 Mn |
| Jun 30, 2024 | 6.44 Mn |
| Mar 31, 2024 | 5.16 Mn |
| Dec 31, 2023 | 10.29 Mn |
| Sep 30, 2023 | 9.58 Mn |
| Jun 30, 2023 | 10.29 Mn |
| Mar 31, 2023 | 9.39 Mn |
| Dec 31, 2022 | 10.29 Mn |
| Sep 30, 2022 | 9.38 Mn |
| Jun 30, 2022 | 8.94 Mn |
| Mar 31, 2022 | 10.29 Mn |
| Dec 31, 2021 | 5.82 Mn |
| Sep 30, 2021 | 9.45 Mn |